Complete Filing Data
ELUTIA INC. reported Stockholders Equity of $27.67 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean ELUTIA INC. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income * | $53.4M | -$53.9M | -$37.7M | -$32.9M | -$24.8M | -$21.8M | -$11.9M |
| Selling And Marketing Expense | $5.8M | $5.0M | $13.1M | $17.9M | $18.8M | $17.6M | $16.2M |
| Revenue From Contract With Customer Including Assessed Tax | $12.3M | $14.5M | $24.7M | $23.8M | $47.4M | $42.7M | $42.9M |
| Research And Development Expense | $4.2M | $3.0M | $4.4M | $7.7M | $9.3M | $6.0M | $2.4M |
| Operating Income Loss | -$26.9M | -$30.7M | -$30.5M | -$35.2M | -$23.0M | -$13.6M | -$8.4M |
| Income Tax Expense Benefit | $13.0K | $7.0K | $28.0K | $34.0K | $55.0K | $26.0K | $30.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$15.9M | -$45.3M | -$41.2M | -$36.1M | -$24.8M | -$21.8M | -$11.9M |
| Gross Profit | $6.6M | $6.7M | $11.1M | $11.6M | $19.0M | $20.6M | $19.8M |
| General And Administrative Expense | $15.1M | $18.1M | $14.1M | $16.1M | $13.7M | $10.6M | $9.6M |
| Cost Of Goods And Services Sold | $5.7M | $7.8M | $13.7M | $12.2M | $28.4M | $22.1M | $23.1M |
| Operating Expenses | $33.5M | $37.4M | $41.6M | $46.8M | $42.1M | $34.2M | $28.2M |
| Interest Expense Recorded As Additional Revenue Interest Obligation | $3.8M | $3.1M | $3.4M | $2.9M | $2.7M | $2.7M | $2.9M |
| Revenue Interest Obligation Noncurrent | $2.8M | $5.5M | $5.4M | $5.9M | $16.5M | $16.6M | $16.6M |
| Revenue Interest Obligation Current | $4.4M | $4.4M | $11.7M | $9.0M | $2.8M | $2.8M | $2.8M |
| Interest Expense | $5.8M | $5.1M | $5.3M | $5.6M | $5.4M | ||
| Other Nonoperating Income Expense | -$2.8M | $1.2M | -$759.0K | $4.2M | $3.6M | -$2.6M | $1.9M |
| Payments On Revenue Interest Obligation | $7.4M | $2.1M | $2.7M | $2.6M | $1.9M | ||
| Income Loss From Continuing Operations Per Basic Share | -$0.38 | -$1.56 | -$2.27 | -$2.62 | |||
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | -$15.9M | -$45.3M | -$41.2M | -$36.2M | |||
| Income Loss From Continuing Operations Per Diluted Share | -$0.64 | -$1.56 | -$2.27 | -$2.62 | |||
| Income Loss From Discontinued Operations Net Of Tax Per Diluted Share | $1.51 | -$0.30 | $0.20 | $0.24 | |||
| Income Loss From Discontinued Operations Net Of Tax | $69.3M | -$8.6M | $3.6M | $3.3M | |||
| Income Loss From Discontinued Operations Net Of Tax Per Basic Share | $1.67 | -$0.30 | $0.20 | $0.24 | |||
| Net Income Loss Available To Common Stockholders Basic | -$24.8M | -$25.3M | -$11.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$3.9M | -$9.6M | -$3.9M | $1.3M | -$28.2M | -$18.0M | -$9.7M | -$10.6M | -$8.0M | -$9.9M | -$9.4M | -$8.1M | -$8.3M | -$2.4M | -$5.1M | -$6.7M | -$5.2M | -$4.6M | -$3.1M |
| Selling And Marketing Expense | $1.6M | $3.8M | $3.0M | $1.2M | $3.3M | $3.3M | $2.8M | $3.0M | $4.7M | $4.4M | $5.4M | $4.8M | $4.8M | $4.8M | $4.7M | $4.3M | $4.1M | $4.5M | $4.4M |
| Revenue From Contract With Customer Including Assessed Tax | $3.3M | $6.3M | $6.0M | $3.7M | $6.3M | $6.7M | $6.1M | $6.4M | $6.4M | $5.8M | $12.6M | $11.5M | $11.5M | $12.2M | $12.9M | $11.8M | $8.6M | $9.9M | $11.1M |
| Research And Development Expense | $1.1M | $1.5M | $905.0K | $702.0K | $1.0M | $1.2M | $557.0K | $869.0K | $1.6M | $1.7M | $2.6M | $2.3M | $2.3M | $1.9M | $1.7M | $1.3M | $1.4M | $1.3M | $507.0K |
| Operating Income Loss | -$5.2M | -$9.9M | -$7.9M | -$9.2M | -$8.5M | -$8.5M | -$7.4M | -$6.3M | -$8.3M | -$9.0M | -$8.2M | -$6.9M | -$7.0M | -$4.6M | -$3.7M | -$2.7M | -$3.8M | -$3.2M | -$1.8M |
| Income Tax Expense Benefit | $8.0K | $8.0K | $8.0K | $8.0K | -$11.0K | $8.0K | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K | $18.0K | $13.0K | $8.0K | $5.0K | $5.0K | $8.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$375.0K | -$9.6M | -$3.9M | $3.3M | -$28.4M | -$18.0M | -$8.5M | -$7.7M | -$9.8M | -$11.0M | -$9.4M | -$8.1M | -$8.3M | -$2.4M | -$5.1M | -$6.7M | -$5.2M | -$4.6M | -$3.1M |
| Gross Profit | $1.9M | $3.1M | $2.5M | $1.8M | $2.8M | $2.8M | $2.8M | $2.7M | $3.4M | $2.9M | $4.9M | $4.3M | $3.7M | $5.6M | $6.3M | $5.5M | $3.8M | $5.2M | $5.5M |
| General And Administrative Expense | $3.5M | $3.7M | $3.9M | $4.3M | $4.7M | $5.1M | $2.8M | $3.9M | $3.5M | $4.3M | $4.7M | $4.0M | $3.5M | $3.5M | $3.6M | $2.7M | $2.1M | $2.6M | $2.4M |
| Cost Of Goods And Services Sold | $1.5M | $3.2M | $3.6M | $1.9M | $3.5M | $3.9M | $3.3M | $3.6M | $3.0M | $2.9M | $7.7M | $7.2M | $7.8M | $6.5M | $6.6M | $6.2M | $4.8M | $4.6M | $5.6M |
| Operating Expenses | $7.1M | $12.9M | $10.4M | $11.0M | $11.3M | $11.3M | $10.2M | $9.0M | $11.7M | $11.9M | $13.1M | $11.2M | $10.7M | $10.2M | $10.0M | $8.2M | $7.5M | ||
| Interest Expense Recorded As Additional Revenue Interest Obligation | $702.0K | $781.0K | $796.0K | $660.0K | $700.0K | $700.0K | $663.0K | $700.0K | $700.0K | $664.0K | $700.0K | ||||||||
| Revenue Interest Obligation Noncurrent | $3.9M | $4.7M | $4.7M | $6.2M | $7.0M | $7.7M | $5.5M | $5.6M | $5.8M | $11.4M | $11.5M | $16.5M | $16.6M | $16.6M | $16.6M | $16.7M | |||
| Revenue Interest Obligation Current | $5.5M | $4.4M | $5.5M | $4.4M | $4.4M | $5.9M | $11.1M | $10.4M | $9.7M | $7.8M | $7.8M | $2.8M | $2.8M | $2.8M | $2.8M | $2.8M | |||
| Interest Expense | $1.3M | $1.4M | $1.5M | $1.4M | $1.2M | $1.2M | $1.2M | $1.3M | $1.4M | $1.4M | $1.5M | $1.4M | $1.4M | $1.2M | |||||
| Other Nonoperating Income Expense | -$1.4M | -$105.0K | -$257.0K | $1.4M | -$758.0K | -$803.0K | $3.6M | -$2.6M | |||||||||||
| Payments On Revenue Interest Obligation | $2.6M | $681.0K | $665.0K | $605.0K | |||||||||||||||
| Income Loss From Continuing Operations Per Basic Share | -$0.01 | -$0.23 | $0.10 | -$1.14 | -$0.75 | -$0.50 | -$0.48 | -$0.61 | -$0.81 | ||||||||||
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | -$383.0K | -$9.6M | $3.3M | -$28.4M | -$18.0M | -$8.5M | -$7.7M | -$9.8M | -$11.0M | ||||||||||
| Income Loss From Continuing Operations Per Diluted Share | -$0.12 | -$0.26 | -$0.27 | -$1.14 | -$0.75 | -$0.50 | -$0.48 | -$0.61 | -$0.81 | ||||||||||
| Income Loss From Discontinued Operations Net Of Tax Per Diluted Share | -$0.07 | -$0.06 | $0.01 | -$0.07 | -$0.18 | $0.11 | $0.08 | ||||||||||||
| Income Loss From Discontinued Operations Net Of Tax | -$3.5M | -$2.1M | $180.0K | -$1.2M | -$2.9M | $1.8M | $1.1M | ||||||||||||
| Income Loss From Discontinued Operations Net Of Tax Per Basic Share | -$0.08 | -$0.06 | $0.01 | -$0.07 | -$0.18 | $0.11 | $0.08 | ||||||||||||
| Net Income Loss Available To Common Stockholders Basic | -$3.9M | $1.1M | -$9.7M | -$8.3M | -$10.2M | -$3.1M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $27.7M | -$46.3M | -$38.6M | -$5.0M | $13.5M | $20.8M | -$55.1M | -$43.4M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $36.4M | $13.2M | $19.3M | $17.0M | $30.4M | $39.5M | $2.6M | $2.4M |
| Cash And Cash Equivalents At Carrying Value | $36.4M | $13.2M | $19.3M | $17.0M | $30.4M | $39.2M | $2.5M | |
| Retained Earnings Accumulated Deficit | -$176.2M | -$229.6M | -$175.6M | -$138.0M | -$105.1M | -$80.3M | -$56.9M | |
| Property Plant And Equipment Net | $2.5M | $671.0K | $172.0K | $245.0K | $1.2M | $1.2M | $988.0K | |
| Prepaid Expense And Other Assets Current | $2.3M | $2.0M | $2.2M | $2.4M | $1.5M | $2.9M | $1.4M | |
| Other Assets Noncurrent | $2.5M | $179.0K | $332.0K | $320.0K | $76.0K | $76.0K | $76.0K | |
| Liabilities Current | $25.1M | $37.8M | $43.0M | $42.6M | $26.0M | $26.8M | $18.3M | |
| Liabilities And Stockholders Equity | $62.4M | $36.1M | $43.4M | $68.8M | $67.2M | $82.8M | $44.8M | |
| Liabilities | $34.7M | $82.4M | $82.0M | $73.9M | $53.6M | $62.0M | $55.4M | |
| Inventory Net | $2.6M | $1.9M | $3.9M | $4.2M | $9.6M | $10.1M | $7.2M | |
| Intangible Assets Net Excluding Goodwill | $1.5M | $2.6M | $11.7M | $15.1M | $18.5M | $21.9M | $25.3M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $23.1M | -$6.0M | $2.3M | -$13.4M | -$9.1M | $36.9M | $177.0K | |
| Assets Current | $55.8M | $26.2M | $31.3M | $50.7M | $47.4M | $59.7M | $18.4M | |
| Assets | $62.4M | $36.1M | $43.4M | $68.8M | $67.2M | $82.8M | $44.8M | |
| Accrued Liabilities Current | $4.4M | $7.1M | $9.5M | $8.8M | $6.4M | $6.3M | $4.0M | |
| Accounts Receivable Net Current | $1.7M | $2.3M | $3.3M | $3.8M | $6.0M | $7.2M | $7.2M | |
| Accounts Payable Current | $4.8M | $4.1M | $3.2M | $1.4M | $1.6M | $2.1M | $2.5M | |
| Long Term Debt Noncurrent | $22.6M | $20.4M | $24.3M | $10.4M | $17.8M | $19.6M | ||
| Payables To Tissue Suppliers Current | $900.0K | $2.5M | $2.3M | $2.5M | ||||
| Other Liabilities Current | $355.0K | $145.0K | $275.0K | $232.0K | $5.0K | |||
| Repayments Of Long Term Debt | $18.6M | $2.8M | $300.0K | $112.0K | ||||
| Other Liabilities Noncurrent | $515.0K | $127.0K | $698.0K | $756.0K | ||||
| Restricted Cash Current | $35.0K | $382.0K | $108.0K | |||||
| Loss Contingency Receivable Current | $4.8M | $4.8M | $2.7M | $13.8M | ||||
| Increase Decrease Contingent Liability | -$9.2M | $5.4M | -$2.3M | $17.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$43.9M | -$41.8M | -$36.5M | -$40.2M | -$64.3M | -$50.3M | -$29.5M | -$22.1M | -$12.2M | -$10.7M | -$1.4M | $6.6M | $7.9M | $15.0M | $16.4M | -$74.9M | -$64.7M | -$59.6M | -$52.4M | -$49.3M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $4.7M | $8.5M | $17.4M | $25.7M | $18.2M | $12.6M | $14.5M | $9.3M | $11.8M | $8.1M | $16.5M | $22.2M | $22.6M | $28.4M | $30.5M | $1.6M | $1.0M | $626.0K | $579.0K | ||
| Cash And Cash Equivalents At Carrying Value | $4.7M | $8.5M | $17.4M | $25.7M | $18.2M | $12.6M | $14.5M | $9.3M | $11.8M | $8.1M | $16.5M | $22.1M | $22.5M | $28.3M | $30.4M | $1.5M | $990.0K | $542.0K | $273.0K | ||
| Retained Earnings Accumulated Deficit | -$247.0M | -$243.1M | -$233.5M | -$220.5M | -$221.8M | -$193.6M | -$166.3M | -$156.6M | -$146.0M | -$132.5M | -$122.6M | -$113.2M | -$96.0M | -$87.7M | -$85.3M | -$74.9M | |||||
| Property Plant And Equipment Net | $2.1M | $2.1M | $1.0M | $693.0K | $159.0K | $171.0K | $175.0K | $1.5M | $1.5M | $1.4M | $1.3M | $1.2M | $1.3M | $1.2M | $1.2M | $1.1M | |||||
| Prepaid Expense And Other Assets Current | $539.0K | $1.1M | $1.6M | $431.0K | $1.1M | $1.9M | $452.0K | $2.4M | $2.4M | $970.0K | $1.8M | $3.0M | $1.3M | $1.8M | $2.4M | $3.7M | |||||
| Other Assets Noncurrent | $2.6M | $2.9M | $826.0K | $1.3M | $1.4M | $383.0K | $155.0K | $1.4M | $1.5M | $89.0K | $76.0K | $76.0K | $76.0K | $76.0K | $76.0K | $76.0K | |||||
| Liabilities Current | $41.3M | $37.9M | $36.9M | $39.7M | $39.8M | $38.1M | $44.7M | $42.9M | $41.4M | $40.2M | $34.7M | $27.3M | $22.5M | $23.6M | $24.8M | $25.6M | |||||
| Liabilities And Stockholders Equity | $29.4M | $33.8M | $39.3M | $48.4M | $41.9M | $35.4M | $54.6M | $52.3M | $60.6M | $61.0M | $52.9M | $59.9M | $59.9M | $69.7M | $74.2M | $46.1M | |||||
| Liabilities | $73.3M | $75.7M | $75.8M | $88.6M | $106.2M | $85.7M | $84.1M | $74.5M | $72.8M | $71.7M | $54.2M | $53.4M | $52.0M | $54.7M | $57.8M | $64.5M | |||||
| Inventory Net | $2.0M | $5.2M | $4.3M | $3.6M | $3.1M | $3.1M | $6.5M | $9.3M | $11.1M | $10.2M | $9.7M | $9.9M | $9.8M | $10.3M | $10.2M | $9.8M | |||||
| Intangible Assets Net Excluding Goodwill | $1.8M | $6.6M | $7.4M | $9.1M | $10.0M | $10.8M | $12.5M | $13.4M | $14.2M | $15.9M | $16.8M | $17.6M | $19.3M | $20.2M | $21.0M | $22.7M | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $4.1M | -$6.7M | -$5.2M | -$8.3M | -$9.0M | -$2.0M | |||||||||||||||
| Assets Current | $18.4M | $22.3M | $30.0M | $37.3M | $30.4M | $24.0M | $39.1M | $36.1M | $43.5M | $43.7M | $34.7M | $41.1M | $39.3M | $48.2M | $51.9M | $22.2M | |||||
| Assets | $29.4M | $33.8M | $39.3M | $48.4M | $41.9M | $35.4M | $54.6M | $52.3M | $60.6M | $61.0M | $52.9M | $59.9M | $59.9M | $69.7M | $74.2M | $46.1M | |||||
| Accrued Liabilities Current | $7.3M | $6.3M | $6.1M | $5.4M | $7.3M | $9.0M | $10.7M | $11.7M | $9.3M | $8.9M | $7.5M | $5.8M | $5.2M | $6.3M | $5.0M | $7.9M | |||||
| Accounts Receivable Net Current | $3.6M | $3.2M | $2.9M | $2.9M | $3.5M | $4.4M | $2.9M | $6.3M | $7.3M | $7.2M | $6.6M | $6.0M | $5.5M | $7.7M | $8.8M | $7.1M | |||||
| Accounts Payable Current | $6.6M | $6.1M | $4.5M | $5.1M | $3.1M | $4.2M | $3.0M | $3.2M | $3.5M | $2.6M | $1.8M | $1.7M | $1.7M | $1.6M | $2.0M | $3.2M | |||||
| Long Term Debt Noncurrent | $21.1M | $21.4M | $21.8M | $22.6M | $18.9M | $19.7M | $25.3M | $24.9M | $24.6M | $20.0M | $7.1M | $8.8M | $12.0M | $13.7M | $15.5M | $21.2M | |||||
| Payables To Tissue Suppliers Current | $798.0K | $907.0K | $906.0K | $707.0K | $2.5M | $2.7M | $3.2M | $3.2M | $2.9M | $2.7M | $2.2M | $2.6M | $2.4M | ||||||||
| Other Liabilities Current | $222.0K | $405.0K | $435.0K | $491.0K | $488.0K | $217.0K | $399.0K | $620.0K | $588.0K | $12.0K | $8.0K | ||||||||||
| Repayments Of Long Term Debt | $2.0M | $1.7M | $300.0K | ||||||||||||||||||
| Other Liabilities Noncurrent | $1.6M | $1.6M | $694.0K | $433.0K | $351.0K | $207.0K | $86.0K | $899.0K | $771.0K | ||||||||||||
| Restricted Cash Current | $22.0K | $109.0K | $83.0K | $66.0K | $91.0K | $100.0K | $50.0K | $84.0K | $306.0K | ||||||||||||
| Loss Contingency Receivable Current | $4.6M | $4.3M | $3.9M | $4.6M | $4.4M | $2.0M | $7.5M | $8.9M | $10.9M | $17.2M | |||||||||||
| Increase Decrease Contingent Liability | -$2.6M | $567.0K | -$1.7M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$44.8M | -$22.7M | -$21.8M | -$21.4M | -$15.4M | -$13.6M | -$7.2M |
| Net Cash Provided By Used In Financing Activities | -$10.6M | $17.1M | $9.8M | $8.5M | $6.7M | $51.2M | $8.0M |
| Share Based Compensation | $5.2M | $7.9M | $2.4M | $3.6M | $3.5M | $779.0K | $208.0K |
| Payments To Acquire Property Plant And Equipment | $1.9M | $654.0K | $346.0K | $540.0K | $369.0K | $640.0K | $577.0K |
| Net Cash Provided By Used In Investing Activities | $78.6M | -$474.0K | $14.2M | -$540.0K | -$369.0K | -$640.0K | -$577.0K |
| Increase Decrease In Inventories | $1.6M | $58.0K | $609.0K | $498.0K | -$563.0K | $2.9M | -$269.0K |
| Increase Decrease In Contract With Customer Liability And Other Liabilities | $1.1M | -$465.0K | -$70.0K | -$571.0K | -$552.0K | -$65.0K | -$927.0K |
| Increase Decrease In Accounts Receivable | -$84.0K | -$527.0K | -$802.0K | $834.0K | -$1.2M | -$64.0K | $30.0K |
| Depreciation Depletion And Amortization | $2.8M | $3.5M | $3.7M | $3.7M | $3.7M | $3.9M | $3.9M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $285.0K | -$743.0K | -$167.0K | $1.5M | -$1.4M | $1.5M | $373.0K |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$6.5M | -$1.1M | -$2.1M | $4.9M | -$420.0K | $1.9M | -$627.0K |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans | 112.0K | 162.0K | 219.0K | 317.0K | 208.0K | ||
| Increase Decrease In Obligations To Tissue Suppliers | $685.0K | $172.0K | -$191.0K | $1.2M | |||
| Proceeds From Repayments Of Lines Of Credit | -$4.8M | -$1.8M | $2.3M | $2.6M | |||
| Increase Decrease In Insurance Settlements Receivable | $86.0K | $2.1M | -$11.1M | $13.8M | |||
| Payments Related To Tax Withholding For Share Based Compensation | $380.0K | $1.2M | $32.0K | $395.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q2 2022 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$8.9M | -$2.6M | -$5.2M | -$10.7M | -$7.4M | -$5.2M | -$3.0M |
| Net Cash Provided By Used In Financing Activities | $13.3M | -$4.1M | $148.0K | -$3.0M | -$869.0K | -$3.7M | $1.1M |
| Share Based Compensation | $1.2M | $2.2M | $684.0K | $1.1M | $677.0K | $54.0K | |
| Payments To Acquire Property Plant And Equipment | $278.0K | $15.0K | $182.0K | $34.0K | $131.0K | $62.0K | |
| Net Cash Provided By Used In Investing Activities | -$278.0K | -$15.0K | -$182.0K | -$34.0K | -$131.0K | -$62.0K | |
| Increase Decrease In Inventories | $375.0K | -$801.0K | $1.0M | $309.0K | $101.0K | $2.0M | |
| Increase Decrease In Contract With Customer Liability And Other Liabilities | -$103.0K | $179.0K | $80.0K | $68.0K | -$67.0K | -$105.0K | |
| Increase Decrease In Accounts Receivable | $584.0K | $1.1M | $504.0K | $14.0K | $1.6M | -$1.6M | |
| Depreciation Depletion And Amortization | $868.0K | $864.0K | $947.0K | $929.0K | $933.0K | $974.0K | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$449.0K | -$168.0K | -$648.0K | $1.6M | -$465.0K | ||
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$225.0K | $2.0M | $409.0K | -$492.0K | -$1.4M | $132.0K | |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans | 80.0K | 70.0K | 148.0K | 192.0K | |||
| Increase Decrease In Obligations To Tissue Suppliers | -$465.0K | $417.0K | $276.0K | $158.0K | |||
| Proceeds From Repayments Of Lines Of Credit | $1.4M | -$3.1M | $1.6M | ||||
| Increase Decrease In Insurance Settlements Receivable | -$867.0K | -$665.0K | -$2.9M | ||||
| Payments Related To Tax Withholding For Share Based Compensation | $152.0K | $6.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Diluted EPS * | $0.87 | -$1.86 | -$2.07 | -$2.38 | -$2.38 | -$8.88 | -$18.48 |
| Weighted Average Number Of Shares Outstanding Basic | 41.4M | 29.1M | 18.2M | 13.8M | 10.4M | 2.9M | |
| Weighted Average Number Of Diluted Shares Outstanding | 45.9M | 29.1M | 18.2M | 13.8M | 10.4M | 2.9M | |
| Earnings Per Share Basic | $1.29 | $-1.86 | $-2.07 | $-2.38 | $-2.38 | $-8.88 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.19 | -$0.26 | -$0.21 | -$0.33 | -$1.13 | -$0.75 | -$0.57 | -$0.65 | -$0.49 | -$0.73 | -$0.69 | -$0.60 | -$0.81 | -$0.23 | -$0.50 | -$15.79 | -$7.99 | -$7.03 | -$4.81 |
| Weighted Average Number Of Shares Outstanding Basic | 42.4M | 41.8M | 38.6M | 32.5M | 24.9M | 23.9M | 17.0M | 16.2M | 16.1M | 13.7M | 13.6M | 13.6M | 10.2M | 10.2M | 10.2M | 648.4K | 648.3K | ||
| Weighted Average Number Of Diluted Shares Outstanding | 47.0M | 46.3M | 42.9M | 35.5M | 24.9M | 23.9M | 17.0M | 16.2M | 16.1M | 13.7M | 13.6M | 13.6M | 10.2M | 10.2M | 10.2M | 648.4K | 648.3K | ||
| Earnings Per Share Basic | $-0.09 | $-0.23 | $-0.10 | $0.03 | $-1.13 | $-0.75 | $-0.57 | $-0.65 | $-0.49 | $-0.73 | $-0.69 | $-0.60 | $-0.81 | $-0.23 | $-0.50 | $-15.79 | $-7.99 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $5.2M | $7.9M | $2.4M | $3.6M | $3.5M | $779.0K | $217.0K |
| Interest Paid Net | $7.5M | $5.3M | $2.3M | $5.5M | $5.0M | $5.1M | $4.4M |
| Additional Paid In Capital | $203.8M | $183.3M | $137.0M | $132.9M | $118.6M | $101.1M | $1.8M |
| Stock Issued During Period Value Employee Stock Purchase Plan | $112.0K | $155.0K | $219.0K | $317.0K | $208.0K | ||
| Legal Fees | $8.5M | $11.4M | $10.0M | $5.2M | $276.0K | ||
| Short Term Borrowings | $1.3M | $3.3M | $8.1M | $6.3M | $1.7M | ||
| Amortization Of Financing Costs | $121.0K | $121.0K | $142.0K | ||||
| Stock Issued During Period Value Stock Options Exercised | $7.0K | $78.0K | $26.0K | $2.0K | $17.0K | ||
| Litigation Reserve Current | $11.2M | $20.4M | $15.0M | $17.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.0M | $1.1M | $1.2M | $1.8M | $2.7M | $2.2M | $615.0K | $687.0K | $684.0K | $297.0K | $1.5M | $1.1M | $1.0M | $885.0K | $677.0K | $58.0K | $72.0K | $54.0K | $49.0K |
| Interest Paid Net | $526.0K | $2.5M | $572.0K | $1.2M | $1.2M | $1.2M | |||||||||||||
| Additional Paid In Capital | $203.0M | $201.3M | $197.0M | $180.3M | $157.5M | $143.3M | $136.8M | $134.4M | $133.8M | $121.9M | $121.3M | $119.8M | $103.9M | $102.7M | $101.8M | ||||
| Stock Issued During Period Value Employee Stock Purchase Plan | $32.0K | $80.0K | $92.0K | $70.0K | $72.0K | $148.0K | $126.0K | $192.0K | $208.0K | ||||||||||
| Legal Fees | $853.0K | $4.0M | $2.6M | $4.7M | $2.3M | $1.8M | $4.1M | $1.3M | $1.9M | $1.5M | $346.0K | $88.0K | $77.0K | ||||||
| Short Term Borrowings | $5.0M | $3.8M | $2.5M | $3.4M | $2.3M | $8.1M | $8.1M | $8.1M | $7.5M | $8.6M | $2.9M | ||||||||
| Amortization Of Financing Costs | $53.0K | $54.0K | $53.0K | $15.0K | $30.0K | $30.0K | |||||||||||||
| Stock Issued During Period Value Stock Options Exercised | $7.0K | $10.0K | $23.0K | $3.0K | $2.0K | ||||||||||||||
| Litigation Reserve Current | $16.4M | $17.0M | $17.8M | $24.3M | $20.2M | $15.6M | $15.7M | $14.5M | $15.6M | $17.6M |
Most recent annual filing with the SEC: March 13, 2026
Data sourced from SEC EDGAR public filings as of August 8, 2026.